Acumen Pharmaceuticals, Inc. - Common Stock (NQ:ABOS)

2.345 +0.365 (+18.43%)

Delayed Quote Updated: 2:48 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Acumen Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >

Acumen Pharmaceuticals to Participate in the UBS Biopharma Conference

November 02, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer’s Disease at the 16th Annual Clinical Trials on Alzheimer’s Disease

October 27, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Present Deeper Insights from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD)

October 04, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals's Earnings: A Preview ↗

August 07, 2023

Via Benzinga

Acumen Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

September 19, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Participate in the H.C. Wainwright Annual Global Investment Conference

September 06, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Upcoming Phase 2 Data Expected For Longeveron's (NASDAQ: LGVN) Drug For the $4+ Billion Alzheimer's Sector – What To Look For ↗

September 06, 2023

Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is expecting data from its phase 2a trial for its Lomecel-B™...

Via Benzinga

Why Shares of Acumen Pharmaceuticals Are Down Tuesday ↗

July 18, 2023

The company announced a $100 million stock sale.

Via The Motley Fool

Acumen Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Highlights

August 08, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Acumen Pharmaceuticals to Report Second Quarter Financial Results on August 8, 2023

August 01, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Neuroinflammation A Key Indicator For Alzheimer’s, But Current Treatments Show Little Success In Reducing Or Even Increase It — Could This Rising Company Have The Answer?

July 27, 2023

--News Direct--

Via News Direct

$40M Bet On Acumen Pharmaceuticals? Check Out These 3 Stocks Insiders Are Buying ↗

July 26, 2023

Although US stocks closed higher on Tuesday, there were a few notable insider trades.

Via Benzinga

MarketBeat Week in Review – 7/17 - 7/21

July 22, 2023

Investor sentiment remains strong but upcoming tech earnings and an expected interest rate hike may provide more clarity on the short-term outlook for stocks

Via MarketBeat

Topics Economy

Acumen Soars on Alzheimer's Study...Street Sees It Doubling

July 19, 2023

Will the $11.00 level be a double-top ceiling…or can Acumen Pharmaceuticals build momentum and climb towards its $25.00 IPO price?

Via MarketBeat

Topics Initial Public Offering

Acumen Announces Pricing of Upsized $130 Million Public Offering

July 18, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

July 18, 2023

Via Benzinga

Why Lixte Biotechnology Shares Are Trading Lower By 26%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

July 18, 2023

Gainers Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) gained 90% to $0.3560 after the company issued strategic update and announced restructuring.

Via Benzinga

Why Biophytis Shares Are Trading Higher By 54%; Here Are 20 Stocks Moving Premarket ↗

July 18, 2023

Gainers Biophytis S.A. (NASDAQ: BPTS) shares surged 53.9% to $3.31 in pre-market trading after the company signed a partnership with SEQENS to produce Sarconeos (BIO101) active compound, the company's...

Via Benzinga

Masimo, Acumen Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗

July 18, 2023

U.S. stock futures traded mixed this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

July 17, 2023

Via Benzinga

Acumen Pharmaceuticals Announces Proposed Public Offering of Common Stock

July 17, 2023

From Acumen Pharmaceuticals, Inc.

Via GlobeNewswire

Playbook Revisited As UNH Beat Could Help Sagging Healthcare Stocks ↗

July 17, 2023

Last week saw a broadening of the rally as many top sectors were up over 3%. But healthcare was among the laggards up only 0.7%.

Via Talk Markets

12 Health Care Stocks Moving In Monday's Intraday Session ↗

July 17, 2023

Via Benzinga

Why Acumen Pharmaceuticals Shares Are Trading Higher By Over 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

July 17, 2023

Gainers ProMIS Neurosciences, Inc. (NASDAQ: PMN) shares jumped 126.6% to $6.37. ProMIS showcased preclinical data at the Alzheimer's Association International Conference 2023 on computationally-derived...

Via Benzinga

Ford Motor Cuts Prices For F-150 Lightning Truck, Microsoft-Sony Sign Agreement for 'Call of Duty,' Alibaba Stock Slips on China's Q2 GDP Sentiment: Today's Top Stories ↗

July 17, 2023

Benzinga

Via Benzinga

US Stocks Edge Higher; NY Empire State Manufacturing Index Falls In July ↗

July 17, 2023

U.S. stocks traded slightly higher this morning, with the Dow Jones moving higher by around 20 points on Monday. Following the market opening Monday, the Dow traded up 0.06% to 34,529.57 while the...

Via Benzinga

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

July 17, 2023

Via Benzinga

Why BYND Cannasoft Enterprises Shares Are Trading Lower By 40%; Here Are 20 Stocks Moving Premarket ↗

July 17, 2023

Gainers

Via Benzinga

Acumen Pharma's Stock Doubles In One Session - Here's Why ↗

July 17, 2023

Acumen Pharmaceuticals Inc (NASDAQ: ABOS) presented topline results from the Phase 1 INTERCEPT-AD trial of ACU193, the first clinical-stage amyloid beta oligomers (AβO) targeting antibody therapy in...

Via Benzinga

Why Is BYND Cannasoft Enterprise (BCAN) Stock Down 46% Today? ↗

July 17, 2023

BYND Cannasoft Enterprise (BCAN) stock is dropping on Monday after the company announced an underwritten stock offering.

Via InvestorPlace

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.